Eligard Kit is owned by Tolmar Therap.
Eligard Kit contains Leuprolide Acetate.
Eligard Kit has a total of 1 drug patent out of which 0 drug patents have expired.
Eligard Kit was authorised for market use on 24 July, 2002.
Eligard Kit is available in powder;subcutaneous dosage forms.
Eligard Kit can be used as method of treating cancer.
The generics of Eligard Kit are possible to be released after 15 October, 2023.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8470359 | TOLMAR THERAP | Sustained release polymer |
Oct, 2023
(4 months from now) |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 24 July, 2002
Treatment: Method of treating cancer
Dosage: POWDER;SUBCUTANEOUS
20
United States
5
Australia
5
Japan
4
Denmark
4
Spain
4
Portugal
4
European Union
3
Austria
3
Germany
3
Brazil
2
Israel
2
Canada
2
Cyprus
2
Hong Kong
2
China
1
Iceland
1
Korea, Republic of
1
New Zealand
1
Slovakia
1
Czech Republic
1
Russia
1
Poland
1
Slovenia
1
Mexico
1
South Africa
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic